Interim Report January – September 2005

• Orders for the newly launched CoroNet patient monitoring system totaled MSEK 20.1. Installations began at the end of September. • Sales reached MSEK 103.3 (118.4). Sales were lower because of the conclusion of the exclusive license agreement with Philips Medical Systems. Medos, which was acquired in May, contributed MSEK 25.4. • Loss after financial items was MSEK 10.7 (profit: 23.7). • Net result after tax was MSEK -9.1 (18.1). • Earnings per share were SEK -0.66 (1.31). • The Group expects a loss after net financial items for the twelve-month period. Third quarter 2005 Sales for the third quarter totaled MSEK 44.9 (39.2). The Medos Group, which was acquired on May 30, 2005, contributed MSEK 19.3 to sales. The Group's loss before tax for the third quarter amounted to MSEK 8.8 (profit: 15.0) and its loss after tax was 7.1 (profit: 10.0). During the quarter Ortivus began installing its newly developed CoroNet cardiology system for customers such as Västra Götaland Region. All cardiac care units at hospitals in the Göteborg area are being equipped with Ortivus' new monitoring system. New orders for CoroNet have exceeded expectations in both Sweden and Finland. The integration of Medos and the launch of Ortivus' Swedish products in the German market are proceeding according to plan. The first order for MobiMed combined with Medos' product offer was signed in October. We have seen a significant inflow of orders for Medos after the end of the period. In accordance with IFRS 2, no charges were taken against earnings for the quarter for expenses associated with the employee stock option program aimed at Ortivus Group senior executives, since the conditions specified for earning these stock options in the criteria approved at this year's annual general meeting were not met. An earlier allocation of MSEK 0.2 was reversed. Täby October 25, 2005 Ortivus AB (publ) Board of Directors Future reporting dates: The yearend report will be published on February 22, 2006 The company's auditors did not review this Interim Report. For more information: Mikael Strindlund, CEO, Ortivus, telephone +46 (0)8-446 45 00 or cell phone: +46 (0)70-269 53 03 or E-mail: mikael.strindlund@ortivus.se Please visit: www.ortivus.com Ortivus AB (Corporate ID no. 556259-1205), Enhagsslingan 5, Box 513, 183 25 Täby, telephone: +46 (0)8-446 45 00.